Experienced in Neuroendocrine Tumor

Ruochuan C. Cheng

Kunming, CN 
Experienced in Neuroendocrine Tumor
Kunming, CN 
OverviewLocationsClinical Research

Overview

Ruochuan Cheng practices in Kunming, China. Cheng is rated as an Experienced expert by MediFind in the treatment of Neuroendocrine Tumor. Their top areas of expertise are Thyroid Cancer, Papillary Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroid Nodule, and Thyroidectomy.

Their clinical research consists of co-authoring 38 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles and participated in 2 clinical trials in the study of Neuroendocrine Tumor.

Locations

Kunming, China
Other Locations
Department Of Head And Neck Tumor, Tianjin, China
Chengdu, 610041, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
View 1 Less Clinical Trial

38 Total Publications

The Natural Course of Low-Risk Papillary Thyroid Microcarcinoma During Pregnancy: A Prospective Active Surveillance Study.
The Natural Course of Low-Risk Papillary Thyroid Microcarcinoma During Pregnancy: A Prospective Active Surveillance Study.
Journal: Thyroid : official journal of the American Thyroid Association
Published: May 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cheng's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile